icon-    folder.gif   Conference Reports for NATAP  
 
  International AIDS Conference
Durban, South Africa
July 18-22 2016
Back grey_arrow_rt.gif
 
 
 
Satisfaction, Tolerability, and Acceptability of Cabotegravir (CAB) + Rilpivirine (RPV) Long-Acting Therapy: LATTE-2 Results
 
 
  Reported by Jules Levin
Durban IAC 2016 July 18-22
 
Miranda Murray,1 David Dorey,2 Sandy Griffith,3 Joseph Mrus,4 William Spreen,3 David Margolis3
1ViiV Healthcare, London, UK; 2GlaxoSmithKline, Mississauga, Ontario, Canada; 3ViiV Healthcare, Research Triangle Park, NC, USA; 4Janssen Research & Development, Raritan, NJ, USA

IAC1

IAC2

IAC3

IAC4

IAC5